Clinical Trials Browser

NETWORK × Multiple Myeloma × Dexamethasone × Clear all

NCT04566328 2026-05-15

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

Multiple Myeloma

NCT07085728 2026-05-15

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Phase 2 Active not recruiting

Multiple Myeloma

NCT06182774 2026-05-12

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT04166565 2026-04-20

EMN19

Phase 2 Active not recruiting

Multiple Myeloma

NCT04667663 2026-04-13

CPD-DARA

Phase 1 Active not recruiting

Multiple Myeloma

NCT06918002 2026-04-02

ElLen

Phase 3 Recruiting

Multiple Myeloma

NCT06932562 2026-03-25

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Phase 3 Recruiting

Multiple Myeloma

NCT05257083 2026-03-17

CARTITUDE-6

Phase 3 Active not recruiting

Multiple Myeloma

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT03180736 2025-12-19

EMN14

Phase 3 Completed

304 enrolled 19 charts 1 FDA

Multiple Myeloma

NCT05028348 2025-12-04

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT01863550 2025-09-08

Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 3 Active not recruiting

Multiple Myeloma

NCT05123131 2025-07-08

Isa-RVD

Phase 2 Active not recruiting

Multiple Myeloma

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Phase 3 Recruiting

Multiple Myeloma

NCT02541383 2025-04-13

Cassiopeia

Phase 3 Completed

1,085 enrolled 22 charts 1 FDA

Multiple Myeloma

NCT03732703 2025-02-14

MyDRUG

Phase 1/2 Completed

Multiple Myeloma

NCT04150965 2025-02-14

Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT

Phase 1/2 Terminated

Multiple Myeloma, Recurrence

NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

Phase 2 Completed

143 enrolled 14 charts

Multiple Myeloma, Recurrence

NCT01857115 2024-11-13

wCCyd

Phase 1/2 Completed

Disease, Multiple Myeloma

NCT04934475 2024-11-07

MIDAS

Phase 3 Active not recruiting

Multiple Myeloma

NCT06189833 2024-04-23

TAURUS

Phase 2 Unknown

Multiple Myeloma

NCT01913730 2023-12-13

Maintenance Therapy With Subcutaneous Bortezomib

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT01346787 2023-09-08

CCD

Phase 2 Completed

Multiple Myeloma

NCT02597062 2023-08-28

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Phase 2 Completed

76 enrolled 9 charts

Multiple Myeloma

NCT00305812 2023-08-04

Lenalidomide and Melphalan in Treating Patients With Previously Untreated Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT02185820 2023-07-03

CPD

Phase 1/2 Completed

Multiple Myeloma

NCT02204241 2023-07-03

CCD

Phase 1/2 Completed

Disease, Multiple Myeloma

NCT00002878 2023-06-15

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00256776 2021-10-18

MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

Phase 3 Terminated

269 enrolled 9 charts

Multiple Myeloma, Recurrence

NCT01045681 2020-12-07

BVD

Phase 2 Completed

Multiple Myeloma

NCT02219178 2020-07-17

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Completed

Multiple Myeloma

NCT00002678 2020-04-02

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Phase 3 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00064337 2018-08-09

S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis

Phase 2 Completed

104 enrolled 6 charts

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00124579 2018-08-09

S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

7 enrolled 6 charts

Multiple Myeloma

NCT03402295 2018-01-18

GBRAM003r

Phase 3 Completed

Multiple Myeloma

NCT00040937 2016-12-08

S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 2 Completed

147 enrolled 6 charts

Multiple Myeloma

NCT00064038 2015-03-25

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Phase 3 Completed

198 enrolled 6 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00002548 2015-03-06

SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

Phase 3 Completed

Multiple Myeloma

NCT00002849 2015-03-06

S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Phase 2 Completed

Immunoglobulin Light-chain Amyloidosis, Multiple Myeloma

NCT00005834 2015-03-06

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

Phase 3 Terminated

Multiple Myeloma

NCT01055301 2015-03-06

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma

NCT00814541 2014-12-31

PAD. ICORG 05-01, V11

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01532856 2012-02-15

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

Phase 3 Unknown

Multiple Myeloma

NCT01370434 2011-06-10

PADinMM

Phase 2 Completed

Multiple Myeloma

NCT01296503 2011-02-15

Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma

Phase 3 Completed

Multiple Myeloma